<DOC>
	<DOCNO>NCT00963703</DOCNO>
	<brief_summary>The purpose study determine well Rituximab work early stage disease effect inflame joint blood cell . This allow investigator get well understanding treatment affect inflame joint rheumatoid arthritis ( RA ) patient .</brief_summary>
	<brief_title>Treatment TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients document rheumatoid arthritis ACR criterion Disease duration &lt; 5 year May previously treat methotrexate , hydroxychloroquine sulfasalazine , either single DMARD combination Tender joint count &gt; = 6 , swell joint count &gt; = 6 , one must knee Corticosteroids &lt; = 10 mg per day permit stable dos least 4 week Patients must consent 2 arthroscopic synovial biopsy procedure History severe allergic anaphylactic reaction monoclonal antibody Previous treatment Rituximab Previous treatment Arava Injected steroid within 4 week day 1 study Treatment investigational agent within 4 week day study Any severe significant medical condition disease know active infection Pregnancy nursing present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>